Director Gabrielle Sulzberger filed a Form 4 with the SEC on November 17, 2026, disclosing two acquisitions of Eli Lilly common stock on November 16, 2026.
Key Highlights
- Reporting person: Gabrielle Sulzberger, identified as a Director of Eli Lilly & Co (NYSE:LLY).
- First acquisition: 3.4633 shares of common stock acquired at $1,431.67 per share on November 16, 2026, via transaction code A.
- Second acquisition: 167.6364 shares of common stock acquired at $1,431.67 per share on November 16, 2026, via transaction code A.
- Post-transaction ownership: Following both transactions, Sulzberger directly beneficially owned 3,187.5446 shares of common stock.
- Deferral plan: The 3.4633 shares were deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan, to be settled in shares following the reporting person's separation from service.
- Signing authority: The form was signed by Jonathan Groff on behalf of Gabrielle Sulzberger pursuant to authorization on file.
Sulzberger's November 16 Acquisitions Under the Lilly Directors' Deferral Plan
According to the filing, Director Gabrielle Sulzberger reported two separate acquisitions of Eli Lilly & Co common stock on November 16, 2026, both at a price of $1,431.67 per share. The first transaction involved 3.4633 shares, and the second involved 167.6364 shares, each recorded under transaction code A, indicating acquisition.
The filing notes that the 3.4633 shares acquired in the first transaction "have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service," according to the explanation of responses. The second acquisition of 167.6364 shares carries no such deferral notation in the filing.
Following both reported transactions, Sulzberger's directly held beneficial ownership stood at 3,187.5446 shares of Eli Lilly common stock, as reported in Table I of the filing. No derivative securities were reported in Table II. The Form 4 was filed on November 17, 2026, with Jonathan Groff signing on behalf of Sulzberger pursuant to an authorization on file.
What Was Disclosed
Gabrielle Sulzberger, a director of Eli Lilly & Co, reported the acquisition of a combined 171.0997 shares of common stock on November 16, 2026, at $1,431.67 per share, with post-transaction direct beneficial ownership of 3,187.5446 shares.




Please wait processing your request...